A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Kwame Raoul is among several state AGs raising the alarm following complaints about online teleheath company Hims & Hers ...

Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...

GLP-1s and nutrition: quality over restriction! Dr Almandoz shares how shifting from restrictive diets to evidence-based, ...

Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss. Now, new research suggested the benefits of the drugs extend beyond ...

Are compounded GLP-1s safe? Dr Ro breaks down the risks, FDA concerns, and telemedicine's role in prescribing these meds — what physicians must know to protect their patients.

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...